SABCS 2022 | SWOG S1207: adjuvant ET +1 yr everolimus shows benefit in premenopausal high-risk HR+/HER2- BC

Lajos Pusztai, MD, Yale School of Medicine, New Haven, CT, provides an overview of the Phase III SWONG S1207 (NCT01674140) randomized, placebo-controlled trial evaluating the role of everolimus in combination with endocrine therapy in the adjuvant setting in patients with high-risk HR-positive, HER2-negative breast cancer. The primary endpoint was invasive disease-free survival (IDFS) and secondary endpoints included overall-survival (OS) and safety. 5-year IDFS was 74.8% in patients treated with everolimus versus 73.9% with placebo. The 5-year OS was 87.6% with everolimus versus 85.5% with placebo. Overall, the trial results were negative. One year of adjuvant everolimus added to standard adjuvant endocrine therapy did not improve IDFS or OS and was associated with low completion rate and increased adverse events. However, a benefit in in IDFS and OS was observed premenopausal patients compared to postmenopausal. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.